BlackRock Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

BlackRock Group’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$27K	Hold	1,735	–	–	﹤0.01%	2952
2016 Q3	$23K	Hold	1,735	–	–	﹤0.01%	2970
2016 Q2	$24K	Hold	1,735	–	–	﹤0.01%	2990
2016 Q1	$26K	Buy	+1,735	New	+$26.5K	﹤0.01%	3009
2015 Q3	–	Sell	-5,570	Closed	-$144K	–	3096
2015 Q2	$144K	Buy	+5,570	New	+$158K	﹤0.01%	2665
2013 Q4	–	Sell	-1,552	Closed	-$59K	–	2799
2013 Q3	$59K	Buy	+1,552	New	+$55.6K	﹤0.01%	2691

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

BlackRock Group's PRTK Position: Q4 2016 in Review

BlackRock Group held its Paratek Pharmaceuticals, Inc. (PRTK) position steady in Q4 2016 at 1,735 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #2952.

BlackRock Group first reported a position in PRTK in Q3 2013 and has held it in 6 quarters since. The position peaked at $144K in Q2 2015. 92 funds tracked by Wall St. Rank hold PRTK as of Q4 2016.

BlackRock Group held 1,735 shares of Paratek Pharmaceuticals, Inc. worth $27K as of Q4 2016.
BlackRock Group left its Paratek Pharmaceuticals, Inc. share count unchanged in Q4 2016.
Paratek Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2952 holding.
BlackRock Group first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2013 and has held it in 6 quarters since.
BlackRock Group's Paratek Pharmaceuticals, Inc. position peaked at $144K in Q2 2015.
92 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.